Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Clearside Biomedi (CLSD)

Clearside Biomedi (CLSD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 299,987
  • Shares Outstanding, K 57,579
  • Annual Sales, $ 7,890 K
  • Annual Income, $ -18,210 K
  • 60-Month Beta 1.44
  • Price/Sales 37.35
  • Price/Cash Flow N/A
  • Price/Book 17.19
Trade CLSD with:

Options Overview

Details
  • Implied Volatility 117.28%
  • Historical Volatility 85.59%
  • IV Percentile 6%
  • IV Rank 11.02%
  • IV High 442.18% on 10/28/20
  • IV Low 77.04% on 12/17/20
  • Put/Call Vol Ratio 0.80
  • Today's Volume 687
  • Volume Avg (30-Day) 1,709
  • Put/Call OI Ratio 0.44
  • Today's Open Interest 14,912
  • Open Int (30-Day) 17,409

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -0.11
  • Number of Estimates 3
  • High Estimate -0.05
  • Low Estimate -0.16
  • Prior Year -0.13
  • Growth Rate Est. (year over year) +15.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.57 +7.66%
on 07/16/21
7.29 -32.51%
on 07/06/21
+0.05 (+1.03%)
since 06/30/21
3-Month
2.23 +120.63%
on 05/18/21
7.29 -32.51%
on 07/06/21
+1.85 (+60.26%)
since 04/30/21
52-Week
1.25 +293.60%
on 10/30/20
7.29 -32.51%
on 07/06/21
+3.25 (+194.61%)
since 07/30/20

Most Recent Stories

More News
Clearside Biomedical to Report Second Quarter 2021 Financial Results and Provide Corporate Update on Tuesday, August 10, 2021

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases,...

CLSD : 4.92 (-5.57%)
Thinking about buying stock in Osmotica Pharmaceuticals, Property Solutions Acquisition, Sio Gene Therapies, Clearside Biomedical, or Sorrento Therapeutics?

/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OSMT, PSAC, SIOX, CLSD, and SRNE.

CLSD : 4.92 (-5.57%)
OSMT : 3.33 (-2.35%)
PSAC : 13.78 (-0.36%)
SIOX : 2.04 (-2.86%)
SRNE : 8.21 (-2.15%)
Thinking about buying stock in Clearside Biomedical, Acorda Therapeutics, Orphazyme, Nano-X Imaging, or Satsuma Pharmaceuticals?

/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CLSD, ACOR, ORPH, NNOX, and STSA.

ACOR : 3.75 (-5.06%)
CLSD : 4.92 (-5.57%)
NNOX : 28.35 (-1.97%)
ORPH : 4.78 (-0.83%)
STSA : 5.24 (-0.19%)
Do Options Traders Know Something About Clearside Biomedical (CLSD) Stock We Don't?

Investors need to pay close attention to Clearside Biomedical (CLSD) stock based on the movements in the options market lately.

CLSD : 4.92 (-5.57%)
Thinking about buying stock in Clearside Biomedical, Uxin, Petco Health and Wellness, Ashford Hospitality Trust, or Uber?

/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CLSD, UXIN, WOOF, AHT, and UBER.

CLSD : 4.92 (-5.57%)
UXIN : 3.68 (-2.39%)
WOOF : 20.63 (-0.29%)
AHT : 16.20 (-8.99%)
UBER : 43.46 (-2.75%)
Clearside Biomedical Announces Positive Safety Results from Cohort 1 of OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD

- CLS-AX 0.03 mg dose delivered via suprachoroidal injection was well-tolerated with no treatment related adverse events -

CLSD : 4.92 (-5.57%)
Ocular Drug Delivery Mode Market Size, Future Scope, Demands and Projected Industry Growths to 2025

Selbyville, Delaware. The report on Ocular Drug Delivery Mode market is a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections...

ALIM : 8.83 (+1.38%)
CLSD : 4.92 (-5.57%)
OCUL : 11.01 (-2.31%)
VRX.TO : 30.80 (-3.33%)
Clearside Biomedical to Participate in Two Upcoming Investor Conferences in June 2021

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases,...

CLSD : 4.92 (-5.57%)
Bausch Health And Clearside Biomedical Announce U.S. FDA Filing Acceptance For XIPERE™ (triamcinolone acetonide suprachoroidal injectable suspension)

and , /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and Bausch + Lomb, its leading global eye health business, along with Clearside Biomedical, Inc. (Nasdaq: CLSD) ("Clearside"),...

BHC : 29.25 (-1.15%)
BHC.TO : 36.50 (-1.00%)
CLSD : 4.92 (-5.57%)
Clearside Biomedical Announces First Quarter 2021 Financial Results and Provides Corporate Update

- Recent New Drug Application Resubmission for XIPERE

CLSD : 4.92 (-5.57%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Clearside Biomedical, Inc. is a biopharmaceutical company is engaged in developing first-in-class drug therapies to treat blinding diseases of the eye using Clearside proprietary suprachoroidal space(TM) microinjector. Its products include CLS-1001 for the treatment of macular edema associated with non-infectious...

See More

Key Turning Points

3rd Resistance Point 5.64
2nd Resistance Point 5.47
1st Resistance Point 5.20
Last Price 4.92
1st Support Level 4.75
2nd Support Level 4.58
3rd Support Level 4.30

See More

52-Week High 7.29
Fibonacci 61.8% 4.98
Last Price 4.92
Fibonacci 50% 4.27
Fibonacci 38.2% 3.56
52-Week Low 1.25

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar